GlassScriptPhysician profile
Clarice M Nelson
NPI 1811251259
$1,633.53
in general payments reported to CMS, 2019-2025
28 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.47 · 2020: $151 · 2021: $459 · 2022: $121 · 2023: $128 · 2024: $461 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $841.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $243.57 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $199.03 | 2020-2025 | |
| Trice Medical, INC. | $194.89 | 2024 | |
| Pfizer INC. | $173.51 | 2021-2025 | |
| Glaxosmithkline, LLC. | $169.33 | 2021-2025 | Bexsero, Penmenvy, Rotarix |
| Amgen INC. | $94.73 | 2019-2024 | Otezla, Repatha |
| Supernus Pharmaceuticals, INC. | $82.80 | 2023-2024 | Qelbree, Qelbree |
| Vertex Pharmaceuticals Incorporated | $43.05 | 2025 | |
| Allergan, INC. | $42.36 | 2020-2021 | |
| Dexcom, INC. | $36.51 | 2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Merck Sharp & Dohme LLC | $32.14 | 2021-2024 | Vaxneuvance, Gardasil 9, Gardasil |
| Astrazeneca Pharmaceuticals LP | $31.47 | 2024-2025 | Airsupra |
| Biohaven Pharmaceuticals, INC. | $29.32 | 2021 | |
| Organon LLC | $28.12 | 2023-2025 | Nexplanon |
| Eisai INC. | $27.57 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $27.55 | 2021-2025 | Mounjaro, Zepbound |
| Teva Pharmaceuticals USA, INC. | $25.93 | 2020 | |
| Kyowa Kirin, INC. | $23.37 | 2025 | |
| Axsome Therapeutics, INC. | $19.73 | 2024 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.57 | 2024 | Jardiance, Tradjenta |
| Medtronic, INC. | $13.74 | 2025 | Intellis Adaptivestim |
| Tris Pharma INC | $12.57 | 2020 | |
| Neos Therapeutics, LP | $12.30 | 2021 | |
| Amarin Pharma, INC. | $12.22 | 2020 | |
| Sanofi Pasteur INC. | $11.82 | 2022 | |
| Genentech USA, INC. | $11.07 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.17 | 2019 | |
| Veran Medical Technologies, INC. | $10.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clarice Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.